Phase 2 N=18 Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy
Multiple Myeloma
Primary: Progression Free Survival — 3; 9 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=120 Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants
Typhoid Fever
Primary: Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer — 100; 100; 100; 11 percentage of subjects
Phase 2 N=200 Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants
Typhoid Fever
Primary: Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer — 100; 85; 100; 89 percentage of subjects
Phase 2 N=66 Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
Prostate Cancer
Primary: Number of Participants With a Pathology Tumor Stage of Less Than or Equal to Prostate Cancer Stage at Which the Tumor is Confined to the Prostate (pT2) — 24; 8…
Phase 2 N=306 Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss
Alopecia · Baldness
Primary: Change From Baseline in Target Area Hair Count (TAHC) — 153.1; 161.1; 145.2; 163.0 terminal hairs/cm^2
Phase 2 N=43 Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)
Cancer of Head and Neck
Primary: The Primary Endpoint is the Local Regional Control Rate Assessed 3 Months Post Completion of Radiation Therapy. — 43 participants
Phase 2 N=43 Neuroprotection With Riluzole Patients With Early Multiple Sclerosis
Multiple Sclerosis
Primary: MRI Parameter- Percent Brain Volume Change for 2 Years — -0.862; -0.49 percent change per year
Phase 2 N=25 RAD001 Plus Carboplatin in Breast Cancer Patients
Breast Cancer
Primary: Clinical Benefit Rate (Complete Response, Partial Response, and Stable Disease That Lasts More Than 6 Months) — 36 percentage of patients
Phase 2 N=38 Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)
Gastrointestinal Neoplasms · Ovarian Neoplasms
Primary: Overall Response — 3 participants
Phase 2 N=13 Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome
Smith-Lemli-Opitz Syndrome
Primary: Hyperactivity Sub-scale of the Aberrant Behavior Checklist-Community (ABC-C). — 8.6; 8.6 units on a scale — p=1.0
Phase 2 N=12 Study of Kuvan Treatment in Adults With GTPCH Deficiency
GTP Cyclohydrolase Deficiency
Primary: Change in BH4 Levels in Cerebral Spinal Fluid — 6; 10.7; 5.3; 13.2 nmol/L
Phase 2 N=169 Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients
Menopause
Primary: Mean Change in Frequency of Moderate to Severe Vasomotor Symptoms (MSVS) Baseline at Week 4 (2-week Period) — 73.5; 69.5; 70.4; 67.9 Number of MSVS/2 weeks — p=0.5730
Phase 2 N=32 Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Complete Response and Confirmed Complete Response — 8; 8 Participants
Phase 2 N=68 Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Primary: Short Term Period: Steady-state Trough Serum Concentration (Cmin) of Abatacept Following Weekly Subcutaneous Dosing in Participants With Active Rheumatoid Arthritis…
Phase 2 N=25 Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
Lymphoma, Mantle-Cell
Primary: Number of Participants With the Indicated Unconfirmed Response (Complete Response, Complete Response Unconfirmed, and Partial Response) — 14; 2; 5 Participants